The global interventional oncology market size is expected to grow from USD 1.9 billion in 2020 to USD 2.9 billion in 2026, at a CAGR of 6.8% during the forecast period. Technological advancements in the market are propelling the growth of the interventional oncology market. Additionally, rising incidence of infectious diseases, and increased funding and public-private investments are some of the key factors driving the growth of the interventional oncology market.
Download a PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=203687164
Based on product, the interventional oncology market is segmented into ablation devices, embolization devices, and support devices. The embolization devices segment accounted for the largest share of 63.8% of the interventional oncology market in 2020. The large share of this segment can be attributed to the rising prevalence of cancer, product enhancements, and the increasing adoption of Yttrium-90 radioembolic agents in emerging countries. Ongoing technological advancements in the field of oncology, rising prevalence of cancer, high healthcare expenditure, are the major factors supporting market growth.
Based on procedure, the interventional oncology market is segmented into thermal tumor ablation, non-thermal tumor ablation, transcatheter arterial chemoembolization (TACE), transcatheter arterial radioembolization (TARE) or selective internal radiation therapy (SIRT), and transcatheter arterial embolization (TAE) or bland embolization. In 2020, the TARE/SIRT procedures segment accounted for the largest market share, mainly due to the rising prevalence of cancer, increasing demand for minimally invasive procedures, growing adoption of embolization procedures, and the clinical efficacy of Yttrium-90 radioembolic agents (which are used in these procedures).
Based on cancer type, the interventional oncology market is segmented into liver cancer, kidney cancer, lung cancer, bone cancer, and other cancers (includes pediatric cancer, prostate cancer, and breast cancer). The liver cancer segment accounted for the largest share of 63.8% of the interventional oncology market in 2020. The large share of this segment can be attributed to factors such as rising cases of liver cancer across the globe and growing initiatives/research activities for developing advanced liver cancer therapies using interventional oncology.
Based on end users, the interventional oncology market is segmented into hospitals, ambulatory surgery centers, and research & academic institutes. Hospitals accounted for the largest share of the market in 2020. The large share of this end-user segment can be attributed to the presence of advanced ICUs & emergency wards in hospitals and the increasing number of surgical procedures performed in hospitals.
The interventional oncology market is segmented into five major regions, namely, North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. In 2020, North America was the largest regional market for interventional oncology, with a share of 43.2%. Factors such as continuous development and commercialization of novel interventional oncology products and favorable reimbursements & insurance coverage drive the market for interventional oncology in North America.
The Asia Pacific is estimated to be the fastest-growing regional market for interventional oncology. This is due to the rising patient population increasing GDP and healthcare expenditure and growing public awareness about various surgical treatments.
Major Players:
Medtronic (Ireland), Boston Scientific (US), BD (US), Terumo (Japan), Merit Medical (US), AngioDynamics (US), J&J (US), Teleflex (US), Cook Medical (US), HealthTronics (US), MedWaves (US), Sanarus (US), IMBiotechnologies (Canada), Trod Medical (US), IceCure Medical (Israel), Mermaid Medicals (Denmark), Interface Biomaterials BV (Netherlands), Guerbet (France), ABK Biomedical (Canada), Shape Memory Medical (US), Endo Shape (US), Monteris Medical (US), Instylla (US), Trisalus Lifesciences (US), Profound Medical Corp (Canada), Sirtex (US), Accuray (US), Baylis Medical (Canada), and ALPINION MEDICAL SYSTEMS (South Korea).
Recent Developments
In 2021, Boston Scientific (US) launched Launched the TheraSphere Y-90 Glass Microspheres
In 2018, Merit Medical Systems (US) launched the Preclude IDeal Hydrophilic Sheath Introducer in EMEA markets
In 2018, IMBiotechnologies (US) launched ‘Ekobi 500 Embolization Microspheres’ with an enhanced feature of detectability using ultrasound technology.
In 2018, Medical City and distributor Gulf Medical Company to install the first IMRIS Surgical Theatre in Saudi Arabia.
In 2018, Medtronic (Ireland) launched its OptiSphere embolization spheres designed for hypervascular tumor embolization in the US
The global oligonucleotide synthesis market is projected to reach USD 19.7 billion by 2029 from USD 8.8 billion in 2024, at a CAGR of 17.5% during the forecast period. The increased demand for oligonucleotide-based drugs like ASOs and siRNAs to treat various neurological and rare disorders such as Duchenne muscular dystrophy (DMD), spinal muscular atrophy (SMA), and hepatic veno-occlusive disease (VOD) drives market growth.
Download a PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=200829350
By product, synthesized oligonucleotides held the second-largest share of the oligonucleotide synthesis market in 2023. The demand for synthesized oligos is increasing due to growing applications of oligonucleotides in various therapeutic, research, and diagnostic applications. Oligo-based drugs is a growing market. Moreover, oligonucleotides are used as probes and primers in PCR and qPCR reactions, DNA sequencing, next-generation sequencing (NGS), fluorescent in situ hybridization (FISH), development of nucleic acid-based microarrays for pathogen detection and screening, genetic disorder identification, the study of DNA protein interactions, gene expression, gene cloning, library construction, and mutation analysis.
Based on applications, the oligonucleotide synthesis market is segmented into therapeutic, research, and diagnostic applications. In 2023, the therapeutic applications segment accounted for the fastest-growing segment of the oligonucleotide synthesis market. The increasing applications of oligos as therapeutic agents (such as antisense oligos and siRNA) used in treating neurological and rare disorders are expected to drive market growth. Ongoing research to expand this therapeutic potential of oligo-based drugs to common diseases such as cardiovascular disorders will further boost the oligonucleotide therapeutic market.
By end user, the pharmaceutical & biotechnology companies accounted for the second-largest share of the oligonucleotide synthesis market in 2023. The use of oligonucleotide synthesis products in drug discovery & development and biotech research is attributed to the market growth. Also, pharmaceutical & biotechnology companies are investing in research activities to develop nucleic-based therapies to combat new diseases such as cardiovascular disorders.
The oligonucleotide synthesis market is divided into North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa. North America, comprising the US and Canada, is the largest regional segment in the oligonucleotide synthesis market. The large share of the North American market is due to substantial government funding for research and development of oligonucleotide-based therapies, the presence of major players in this market segment, and growing awareness about alternative medicines among the population.
Europe held the second-largest share of the market globally. Growth in the European market can be attributed to factors such as the presence of a large number of academic and research institutes in the region, such as Harvard, growing investments by key market players, and increasing focus on R&D activities.
Key players in the market include Danaher Corporation (US), Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Eurofins Scientific (Luxembourg), LGC Limited (UK), Agilent Technologies, Inc. (US), Kaneka Corporation (Japan), Maravai Lifesciences Holdings, Inc. (US), Azenta, Inc. (US), Twist Bioscience Corporation (US) and Genscript Biotech Corporation (US). Prominent players in the oligonucleotide-based drugs (therapeutic applications) market are Biogen Inc. (US), Alnylam Pharmaceuticals, Inc. (US), Sarepta Therapeutics, Inc. (US), Astrazeneca (UK), Astellas Pharma Inc. (Japan), Jazz Pharmaceuticals Plc (Ireland), Nippon Shinyaku, Co. Ltd. (Japan), Ionis Pharmaceuticals, Inc. (US) and Novartis AG (Switzerland).
Recent Developments of Oligonucleotide Synthesis Industry:
In November 2023, LCG Biosearch Technologies, a business unit of LGC Limited, acquired PolyDesign to enhance its oligonucleotide synthesis capabilities using PolyDesign’s frit technology.
In October 2023, Integrated DNA Technologies (IDT), a subsidiary of Danaher Corporation, opened its therapeutic oligonucleotide manufacturing facility in Coralville, Iowa. This facility will produce reagents for cGMP cell & gene therapy, including single-guide RNAs and HDR donor oligos.
The global 3D cell culture market size is estimated to reach USD 2.5 billion by 2028 from USD 1.3 billion in 2023, at a CAGR of 14.6% during the forecast period. Increased focus on development of alternatives to animal testing, rising government support and funding for 3D cell culture market and augmented demand for personalized medicine is propelling the market growth of 3D cell culture market.
Download a PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=191072847
Based on the product, the 3D cell culture market is segmented into scaffold-based 3D cell cultures, scaffold-free 3D cell cultures, microfluidics-based 3D cell cultures, and magnetic & bioprinted 3D cell cultures. Scaffold-based 3D cell cultures accounted for the largest share of this market in 2022. The dominant share of the segment is mainly due to advantages of scaffold-based cell culture such as the availability of attachment points, & support and structural rigidity.
Based on application, the 3D cell culture market is segmented into cancer & stem cell research, drug discovery & toxicology testing, and tissue engineering & regenerative medicine. Cancer & stem cell research accounted for the largest market share of the market in 2022. The increasing prevalence of cancer and growing funding for cancer research from the government and the private sector are some of the major factors favouring the growth of this application segment.
On the basis of end users, the 3D cell culture market is segmented into pharmaceutical & biotechnology companies, research institutes, the cosmetics industry, and other end users. Pharmaceutical & biotechnology companies accounted for largest share of the 3D cell culture market in 2022. The growing preference for alternative testing models over animal techniques and adoption of 3D cell culture model are the factors driving the growth of this end user segment.
Based on region, the global 3D cell culture market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America had the largest share of the market In 2022. Asia Pacific region is likely to grow at a faster pace during the forecast period of 2023-2028. The factors attributable to the faster growth rate are well-established pharmaceutical & biotechnology companies, increased adoption of 3D cell culture in personalized medicine and rise in fundings by government for 3D cell culture research. Asia Pacific region is anticipated to grow at faster pace.
The 3D cell culture market is consolidated, with a small number of players competing for market shares. Thermo Fisher Scientific. Inc. (US), Merck KGaA (Germany), Corning Incorporated (US), Lonza (Switzerland), and Avantor Inc. (US) are some of the leading players in this market.
Recent Developments of 3D Cell Culture Industry
In October 2022, Corning launched the Elplasia 12K flask featuring a unique microcavity geometry that enables easy spheroid formation, culture, treatment, assessment, and harvest, with approximately 12,000 spheroids of uniform size and shape per flask, generating 125 times more yield than conventional 96-well spheroid plates.
In March 2021, Thermo Fisher Scientific launched a plasma-like medium, a cell culture medium that mimics the metabolic profile of human plasma, designed to provide researchers with a realistic view of cell growth within the human body.
The global patient handling equipment market is estimated to reach USD 14.0 billion by 2027 from USD 10.4 billion in 2022, at a CAGR of 6.2% during the forecast period. The growth of this market is highly fueled by factors such as the increasing number of geriatric and obese populations, rising number of patient admissions in hospitals, high risk of injuries to caregivers during the manual handling of patients, and the implementation of regulations and guidelines in ensuring the safety of healthcare worker during the manual lifting process. However, inefficient training provided to caregivers for the proper care of patient handling equipment is a major factor hindering the growth of market.
Download a PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=186358368
In this report, the patient handling equipment market is segmented on the basis of type, end user, and region. By type, patient transfer devices accounted for the largest share. The largest share of this segment can highly be attributed to the rising number of hospital beds, ceiling lifts and the increasing adoption of patient lifts for handling bariatric patient.
By end user, the patient handling equipment market is segmented into home-care settings hospitals, & and other end users. In 2021, the hospitals segment accounted for the largest share of the patient handling equipment market. Largest share is attributed due to the increasing number of patient population, growing geriatric population, rising number of disabled people, and the increasing number of accidents occurs during the patient handling process.
In 2021, Europe accounted for the largest share of the global patient handling equipment market. The large share of this regional segment is due to the increasing number of government and non-government initiatives and programms regarding the adoption of safe and proper patient handling equipment and the presence of broad range of patient handling equipment manufacturers in Europe. The Asia Pacific patient handling equipment market is expected to grow at the highest CAGR during the forecast period of 2022-2027. The rising number of healthcare facilities in Asian countries is attributed to the market growth in Asia Pacific.
The key players operating in the patient handling equipment market include include Arjo (Sweden), Baxter International Inc. (US), Savaria (Canada), Invacare Corporation (US), Stryker (US), Drive DeVilbiss Healthcare (US), Etac AB (Sweden), GF Health Products, Inc. (US), V. Guldmann A/S (Denmark), Joerns Healthcare LLC (US), Medline Industries, Inc. (US), Prism Medical UK Ltd. (UK), LINET (Czech Republic), Stiegelmeyer GmbH & Co. KG (Germany), Benmor Medical (UK), Malvetio Spa (Italy), EZ Way, Inc. (US), Ossenberg GmbH (Germany), Antano Group (Italy), Winncare (UK), Getinge AB (Sweden).
Recent Developments
In September 2022, Handicare offers an expanded portfolio, including the Garaventa Lift range of wheelchair platform lifts, as well as new and improved products, such as the 4000 curved stairlifts.
In May 2022, Invacare launched Birdie Evo XPLUS, an innovative patient lift solution for post-acute care settings. With its sleek and modern design, it provides innovative technology that helps maximize comfort and security when lifting or transferring a patient to or from a bed, chair or floor.
In March 2022, Stryker launched the Multi-Position MATS Mobile Air Transfer System, that prevents patients from sliding during tilt procedures and protect nurses during pre- and post-surgical lateral transfers.
In May 2021, Hill-Rom participated in the fire-side chat in the UBS Global Healthcare Virtual Conference to support its healthcare business.
The global enteral feeding devices market is projected to reach 5.6 billion in 2029 from USD 4.0 billion in 2023, at a CAGR of 6.2% between 2023 and 2029. The rising technological advancemnets and increasing geriatric population is driving the growth of the market. The As the global population ages, the number of individuals requiring enteral feeding is expected to rise.
Download a PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=183623035
Elderly patients often experience age-related decline in appetite or swallowing difficulties, making enteral feeding a vital support system.
Based on type, the enteral feeding devices market is segmented into enteral feeding tubes, enteral feeding pumps, administration sets, enteral syringes and consumables. The enteral feeding tubes accounts for the largest share in the enteral feeding devices market, Enteral feeding tubes are a crucial component of enteral feeding devices. They act as a conduit to deliver liquid nutrition directly into a patient’s stomach or small intestine, bypassing the mouth and esophagus. Enteral feeding tubes are essential components of enteral feeding devices, providing a safe and reliable way to deliver essential nutrients to patients who cannot consume food orally which is expected to drive the segment growth.
Based on application, the enteral feeding devices market is segmented into oncology, gastrointestinal diseases, nuerological diseases, diabetes, hypermetabolism and other applications. The oncology accounts for the largest share in the enteral feeding devices market, cancer and its treatment (surgery, radiation, chemotherapy) can significantly impact a patient’s appetite and ability to absorb nutrients. Enteral feeding ensures they receive the necessary calories, proteins, vitamins, and minerals to support their immune system, fight infection, and promote healing which is expected to drive the market growth.
In 2023, North America accounted for the largest share of the enteral feeding devices market, followed by Europe and Asia Pacific. The United States and Canada have well-equipped hospitals and a strong focus on advanced medical care, which supports the adoption of enteral feeding devices, also compared to established markets like North America and Europe, the Asia Pacific region often offers lower labor costs, making it an attractive option for companies seeking to optimize manufacturing expenses.
Additionally, several countries in the region, like China and India, have developed a robust infrastructure for manufacturing pharmaceuticals and medical devices which is expected to lead to Asia Pacific growing at the fastest rate during the forecast period.
The major players in the enteral feeding devices market include include The prominent players in the medical device contract manufacturing market include Fresenius SE & Co. KGAA (Germany), Cardinal Health, Inc. (US), Nestlé S.A. (Switzerland), Avanos Medical, Inc. (US), Danone S.A. (France), Becton, Dickinson and Company (US), B. Braun Melsungen AG (Germany), CONMED Corporation (US), Cook Medical (US), Moog Inc. (US), Boston Scientific Corporation (US), Baxter International Inc. (US), Vygon (France), and Other players in the enteral feeding devices market are Applied Medical Technology (US), Amsino International Inc. (US), Omex Medical Technology (India), Danumed Medizintechnik (Germany), Medline Industries, Inc. (US), Fuji Systems (Japan), Kentec Medical (US), Dynarex Corporation (US), Vesco Medical LLC (US), Medela AG (Switzerland), Alcor Scientific (US), and Romsons (India)
Recent Developments of Enteral Feeding Devices Industry:
In September 2022, Cardinal Health, Inc. (US) announced the partnership with Kinaxis (Canada) to enhance the Kinaxis RapidResponse Platform used for supply chain agility and medical product visibility.
In November 2022, Boston Scientific signed an agreement for the acquisition of Apollo Endosurgery, Inc.,. This agreement includes devices, which are used during endoluminal surgery (ELS) procedures, to close gastrointestinal defects, manage gastrointestinal complications, and aid in weight loss for patients suffering from obesity.
In March 2021, Applied Medical Technology, Inc. (US) launched its gastric-jejunal enteral feeding tube family (G-JETs) to include the low-profile micro-G-JET to link up the enteral nutrition needs of pediatric patients.
In March 2022, Vygon Group (France) announced the acquisition of distributor Macatt Medica (Peru). The acquisition is expected to grow the presence of Vygon Group (France), in the South American region, specifically for its broad range of enteral feeding products.
According to the new market research report “Protein Expression Market by Type (E.Coli, Mammalian, CHO, HEK 293, Insect, Pichia, Cell-free), Products (Reagents, Vectors, Competent Cells, Instruments, Service), Application (Therapeutic, Industrial), End User, and Region – Global Forecast to 2027″, The global protein expression market is expected to reach USD 5.4 billion in 2027 from USD 2.9 billion in 2022 at a CAGR of 13.3% during the forecast period.
Download a PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=180323924
Factors such as growing pharmaceutical and biotechnology industries, rising adoption of recombinant-based protein expression as well as increasing public and private support through initiatives and funding are favouring the growth of this market. However, the high cost of protein expression reagents and instruments is likely to restrain the growth of this market.
Based on system type, the protein expression market is segmented into mammalian cell expression systems, prokaryotic expression systems, insect cell expression systems, yeast expression systems, cell-free expression systems, and algal-based expression systems. The mammalian cell expression systems segment accounted for the largest share of the global protein expression market in 2021.
Based on application, the protein expression market is segmented into therapeutic, research and industrial applications. In 2021, the therapeutic applications segment accounted for the largest share of the global protein expression market. Factors such as an increase in protein-based research and the rising prevalence of chronic diseases across the globe contribute to the large share of this market.
Based on product & service, the protein expression market is segmented into reagents, expression vectors, competent cells, instruments, and services. The reagents segment accounted for the largest share of the global protein expression market in 2021. Factors such as the increasing research activities in the field of protein expression as well as the large-scale production of antibodies and vaccines are responsible for large share of this market.
Based on end users, the protein expression market is segmented into pharmaceutical and biotechnology companies, contract research organizations and contract development and manufacturing organizations (CROs and CDMOs), academic research institutes, and other end users. In 2021, the pharmaceutical and biotechnology companies segment accounted for the largest share of the global protein expression market due to an increase in protein research to understand biological systems and the rising production of recombinant therapeutic proteins for disease treatment.
Geographical Growth Scenario:
Based on region, the protein expression market is segmented into North America, Europe, Asia Pacific, Rest of the world (Latin America, and the Middle East & Africa). In 2021, North America accounted for the largest share of the global protein expression market, followed by Europe. Factors such as growth in the biotechnology and pharmaceutical industries, the rising prevalence of chronic disorders, and an increase in protein-based therapeutics research investments in the region contribute to its large share. The APAC market is projected to grow at the highest CAGR during the forecast period.
Key Players:
Thermo Fisher Scientific, Inc (US), Merck KGaA (Germany), GenScript Biotech Corporation (US), Agilent Technologies, Inc. (US), Takara Bio, Inc. (Japan), Bio-Rad Laboratories, Inc. (US), Qiagen N.V (Netherlands), Charles River Laboratories, Inc. (US), Danaher Corporation (US), Sartorius AG (Germany), Corning Incorporated (US), FUJIFILM Irvine Scientific, Inc. (Japan), Lonza Group AG (Switzerland), Bioneer Corporation (South Korea), Promega Corporation (US), Oxford Expression Technologies Ltd. (UK), ProteoGenix (France), Abeomics, Inc. (US), New England Biolabs, Inc. (US), Promab Biotechnologies (US), Sino Biological, Inc. (China), Jena Bioscience (Germany), Lifesensors, Inc. (US), Leading biology, Inc. (US), and Peak Proteins (UK).
Recent Developments:
In June 2021, Thermo Fisher Scientific Inc. (US) and Advanced Electrophoresis Solutions Ltd. (AES) (Canada) signed an agreement to combine essential protein separation techniques with mass spectrometry (MS) to advance therapeutic protein development through streamlined characterization.
In June 2020, Lonza Group AG (Switzerland) launched GSv9, a chemically defined media and feeds platform specifically developed to enhance the performance of the GS Gene Expression System for optimized recombinant protein production.
The report “Autoimmune Disease Diagnosis Market by Product (Consumables, Assay Kits, Instruments), Test Type (Inflammatory Markers, Routine Laboratory Tests), Disease (RA, SLE, Thyroiditis, Scleroderma), End User (Hospitals, Clinical Labs) – Global Forecast to 2025″ The global autoimmune disease diagnosis market size is projected to reach USD 6.3 billion by 2025 from USD 4.1 billion in 2020, growing at a CAGR of 8.9% from 2020 to 2025. Factors driving the growth of this market include high incidence and large economic burden of autoimmune diseases, increasing healthcare expenditure, and growing access to medical insurance in the US.
Download PDF Brochure@ https://www.marketsandmarkets.com/pdfdownload.asp?id=174826519
By product and service, the Autoimmune Disease Diagnosis Market is classified into consumables & assay kits, instruments and services. The consumables & assay kits segment is expected to lead the global autoimmune disease diagnosis in 2017. Factors driving the growth of this segment include increasing adoption of consumables in hospitals and clinical laboratories, rising incidence of autoimmune diseases, and increasing demand for quick results.
On the basis of test type, the Autoimmune Disease Diagnosis Market is categorized into routine laboratory tests, inflammatory markers, autoantibodies and immunologic tests, and other tests. In 2017, the routine laboratory tests segment is estimated to account for the largest share of the global Autoimmune Disease Diagnosis Market. The increasing incidence autoimmune diseases, along with increasing adoption of routine laboratory tests for a variety of diseases are the key factors driving the growth of this end-user segment.
By disease, the market is segmented into systemic lupus erythematosus, rheumatoid arthritis, Sjögren’s syndrome, thyroiditis, scleroderma, and other diseases. The rheumatoid disease segment is expected to account for the largest share of the global autoimmune disease diagnosis in 2017. The growth of this segment is mainly driven by the increasing incidences of the disease.
On the basis of end user, the Autoimmune Disease Diagnosis Market is categorized into clinical laboratories, hospitals, and other end users. The clinical laboratories segment is estimated to account for the largest share of the global Autoimmune Disease Diagnosis Market during the forecast period. The heavy burden of autoimmune diseases, along with the accessibility and availability of diagnosis and treatment instruments in clinical laboratories in a short period of time are the key factors driving the growth of this end-user segment.
Based on region, the Autoimmune Disease Diagnosis Market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). North America is expected to dominate the Autoimmune Disease Diagnosis Market in 2017. This is attributed to factors such as accessibility to advanced technologies and opportunities for advanced autoimmune diagnostic testing and screening, growing incidence of autoimmune diseases, and technological advancements of autoimmune disease diagnosis in the region as compared to other regions.
Key players in the Autoimmune Disease Diagnosis Market include Thermo Fisher Scientific. (US), Danaher (US), HYCOR Biomedical (US), Siemens (Germany), Bio-Rad Laboratories. (US), and Abbott (US).
According to the new market research report “US Healthcare/Hospital Food Services Market by Type (Patient Dining (Clinical Nutrition, Regular Diet), Retail Services, Vending, Shops), Settings (Acute Hospitals, ASC, Long-term Care, Nursing and Rehabilitation Centers, Non – acute) – Forecast to 2026″, published by MarketsandMarkets™, the US Healthcare Food Services Market is projected to reach USD 22.8 billion by 2026 from USD 13.2 billion in 2021, at a CAGR of 11.5% during the forecast period.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=170935372
The growth of this US Hospital Food Services Market is mainly attributed to the increasing prevalence of and awareness about chronic diseases, growing focus on improved patient food experience, availability of customized food options based on diet requirements, hospital restrictions for outside food items, and the cost-effectiveness of foodservice outsourcing. On the other hand, the reluctance among OPD patients to pay for food services, pricing challenges, and the shortage of staff are expected to restrain the growth of this market.
The hospital food service industry has been negatively impacted by the pandemic. A reduction in the number of hospitalizations (due to the postponement of elective surgeries in the first 2 quarters of 2020) reduced the overall patient pool, including outpatient visits for consultations. Also, with the increasing requirement of cleanliness and disinfection to reduce the spread of the virus, operational costs increased for hospitals. In this scenario, hospitals adopted creative solutions to address the restrictions and limitations. For instance, hospitals turned to pre-packaged, grab-and-go options throughout the pandemic to sustain their ability to serve customers while decreasing contact. Some facilities began taking advanced to-go orders for team members, patients, and customers to reduce long lines and bottlenecks during peak rush times. Many hospitals have also transformed their self-serve stations into an assembly-line format. Team members handle each step in the process to help consumers customize their meals while minimizing the risk for cross-contamination. Due to the disruptions in the supply chain, many hospitals narrowed their food options and undertook a more need-based approach. This strategy helped hospital foodservice operations sustain retail sales while becoming more efficient in purchasing and inventory.
Food distribution and meal ordering were the two aspects most impacted by COVID-19. Foodservice staff was not allowed into wards with COVID-19 patients to hand out meals. As a result, nursing staff working in these wards were required to perform this task. Hospitals that had been using tablets to take meal orders from patients were forced to change to paper menus that could be discarded after use to minimize the risk of spreading the virus. Some hospitals also created meal-ordering applications for mobile devices, or they would call patients on phones to take their meal orders without any face-to-face interactions. All COVID-19 hospitals were concerned about the safety of kitchen staff during the dishwashing process. To overcome this, some hospitals replaced reusable crockery and cutlery with disposable cutlery and crockery. However, it resulted in increased plastic waste.
Based on type, the US healthcare/hospital food services market is segmented into patient & dining services, retail services, vending & shops (micro-markets), and other services. In 2020, The increasing demand for nutritious food among patients, convenience and comfort provided by room services, availability of customized food options based on diet requirements, and hospital restrictions on outside food items are the major factors driving the growth of this market segment. The retail services segment is estimated to grow at the highest CAGR during the forecast period. The high growth of this segment can be attributed to the increasing availability of various healthier food options with improved quality and taste, ease of accessibility to nutritious meals for hospital staff and visitors, and the growing patient flow in healthcare facilities.
Major Players:
The prominent players in the US healthcare/hospital food services market are Compass Group plc (UK), Sodexo (France), Aramark (US), Elior Group (France), Healthcare Services Group, Inc. (US), ISS World (US), Culinary Services Group (US), Metz Culinary Management (US), AVI Foodsystems, Inc. (US), Thomas Cuisine (US), Hospital Housekeeping Systems (HHS) (US), Whitsons Culinary Group (US), The Nutrition Group (US), Food Management Group, Inc. (FMG) (US), and Prince Food Systems (US).
The global companion diagnostics market is projected to reach USD 13.6 billion by 2029 from USD 7.5 billion in 2024, at a CAGR of 12.6% during the forecast period. The growth of the companion diagnostics market is primarily driven by several key factors, including a large patient pool undergoing advanced medical testing, high levels of drug development activity, a structured regulatory framework in the region, and policy programs aimed at providing effective care to patients with cancer.
Download a PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=155571681
Based on product & service, the companion diagnostics market is categorized into assays, kits & reagents, instruments/systems and software & services. In 2023, the segment comprising assays, kits, & reagents held the largest share of the companion diagnostics market. This substantial share is due to the wide array of available products, the increasing utilization of assays and kits across various therapeutic fields, and the growing demand for these products in both basic research and commercial applications.
Based on technology, the companion diagnostics market is segmented into into polymerase chain reaction (PCR), in situ hybridization (ISH), next-generation sequencing (NGS), immunohistochemistry (IHC), and other technologies. In 2023, the PCR segment held the predominant market share in the companion diagnostics market. This significant share is attributed to the user-friendly nature and widespread accessibility of PCR kits & reagents in companion diagnostic testing. Additionally, the expanding applications of PCR in the high-throughput detection of gene mutants with limited or low allele frequency, coupled with its quick turnaround time compared to other technologies, contribute to the dominance of the PCR segment.
Based on indication, the companion diagnostics market is categorized into segments including cancer, cardiovascular diseases (CVDs), neurological diseases, infectious diseases, and other indications (inflammatory and inherited diseases, among others). In 2023, the cancer segment held the largest portion of the market. This notable share is driven by several factors, including the rising global incidence of cancer, the expanding role of companion diagnostics in personalized medicine treatments for cancer, the growing importance of biomarkers in cancer diagnosis, advancements in molecular-level cancer diagnostics technology, and the availability of funding for cancer research.
Based on sample type, the companion diagnostics market is segmented into liquid, blood, and other sample types. In 2023, the tissue sample segment accounted for the largest share of the companion diagnostics market. Using tissue samples in companion diagnostics testing offers several advantages, primarily in providing more accurate and reliable results compared to other types of sample.
Categorized by end user, the companion diagnostics market is divided into pharmaceutical & biotechnology companies, reference laboratories, CROs, and other end users (including physician & hospital laboratories, and academic medical centers). In 2023, the pharmaceutical & biotechnology companies segment dominated the companion diagnostics market. This segment’s significant share is linked to the increasing utilization of companion diagnostics in drug development and the rising importance of companion diagnostic biomarkers. Furthermore, the increasing demand for personalized medicine and the necessity for targeted therapies across diverse diseases and disorders are anticipated to fuel the adoption and demand for companion diagnostics among pharmaceutical & biotechnology companies.
The global companion diagnostics market is divided into six primary regions: North America, Europe, Asia Pacific, Latin America, the Middle East & Africa, and GCC countries. Among these regions, North America held the largest regional market share for companion diagnostics. The substantial presence of leading companion diagnostics vendors and national clinical laboratories, coupled with the easy access to technologically advanced devices and instruments, contribute to North America’s significant share in this market. Furthermore, the highly developed healthcare systems in the US and Canada also play a role in this regional dominance.
The major players in this market are F. Hoffmann-La Roche Ltd (Switzerland), Agilent Technologies, Inc. (US), QIAGEN (Netherlands), Thermo Fisher Scientific Inc. (US) and Abbott (US). These players lead the market because of their extensive product portfolios and wide geographic presence. These dominant market players also have numerous advantages, such as more robust marketing and distribution networks, larger budgets for R&D, and better brand recognition.
The global digital diabetes management market is projected to reach USD 35.8 Billion by 2028 from an estimated USD 18.9 Billion in 2023, at a CAGR of 13.6% during the forecast period. The growing number of people with diabetes has led to an increased focus on developing and adopting better diabetes care solutions. Advances in technology have made it possible to create more flexible and sophisticated solutions. The increasing use of cloud-based enterprise solutions and connected devices and apps are also driving market growth. However, high device costs, lack of reimbursement in developing countries, and the preference for traditional diabetes management devices are expected to slow market growth.
Download a PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=144725893
The digital diabetes management market offers a wide range of devices, apps, data management software & platforms, and services. Smart glucose metres, continuous glucose monitoring (CGM) systems, smart insulin pens, smart insulin pumps/closed-loop systems, and smart insulin patches are included in the devices segment. Similarly, the digital diabetes management apps segment is further sub-segmented into diabetes & blood glucose tracking apps and obesity & diet management apps. In 2022, the devices segment held the largest market share for digital diabetes management, with 76.4%. Factors such as the increasing demand for wireless and wearable devices for diabetes management, growing acceptance of smart insulin pumps & pens for insulin delivery, and the growing awareness about continuous glucose monitoring in patients are driving the market growth.
Different types of digital diabetes management device studied in the report are handheld devices and wearable devices. Among these, the The market for digital diabetes management devices in 2022 was dominated by wearables, with a share of 60.3%. By 2028, this market is expected to have grown from USD 8,876.3 million in 2023 to USD 18,557.3 million. Technology advancements like closed-loop pump systems, smart insulin patches, and other pipeline devices, as well as factors like the growing use of smart insulin pumps and insulin patches for self-insulin delivery in diabetes management, are all the factors that are boosting the wearable devices segment’s growth..
Various end users of the digital diabetes management market are self/home healthcare, hospitals & specialty diabetes clinics, and academic & research institutes. The self/home healthcare accounted for the largest share of 79.9% of the digital diabetes management market in 2022. The large share of this segment can mainly be credited to technological advancements and a shift toward home care and self-management of diabetes.
North America is estimated to grow at the highest CAGR during the forecast period. The region also accounted for the largest market share of 45.3%, followed by Europe with a share of 28.1% in 2022. Various factors attributing to the growth of the digital diabetes management market in North America are growing adoption of connected diabetes management devices, high adoption of diabetes management apps, growing demand for integrated hybrid closed-loop systems, favorable reimbursement policies, and government initiatives to promote digital health in the region.
Furthermore, In Asia Pacific, countries such as China and India have a high prevalence rate of diabetes, primarily due to the increasing urbanization, population and lifestyle changes. The increasing incidence of diabetes, rising awareness, high undiagnosed population, and the rising penetration of smartphones and tablets have propelled the adoption of digital diabetes management solutions in the region.
The prominent players operating in the global digital diabetes management market are Medtronic (Ireland), B. Braun Melsungen AG (Germany), Dexcom, Inc. (US), Abbott Laboratories (US), F. Hoffmann-La Roche (Switzerland), Insulet Corporation (US), Tandem Diabetes Care (US), Ascensia Diabetes Care Holdings AG (Switzerland), LifeScan, Inc. (US), Tidepool (US), AgaMatrix (US), Glooko, Inc. (US), DarioHealth Corporation (Israel), One Drop (US), Dottli (Finland), Ypsomed Holding AG (Switzerland), ARKRAY (Japan), ACON Laboratories, Inc. (US), Care Innovations, LLC (US), Health2Sync (Taiwan), Emperra GmbH E-Health Technologies (Germany), Azumio (US), Decide Clinical Software GmbH (Austria), Pendiq GmbH (Germany), and BeatO (India).